These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2498124)

  • 1. Hemolytic anemia and F. VIII concentrate.
    Girelli G
    Eur J Haematol; 1989 Apr; 42(4):414. PubMed ID: 2498124
    [No Abstract]   [Full Text] [Related]  

  • 2. [Severe serogenic hemolytic anemia caused by anti-D fraction in factor VIII concentrate].
    Schricker KT; Schrenk KH
    Thromb Diath Haemorrh; 1972 Jul; 27(3):523-8. PubMed ID: 4197045
    [No Abstract]   [Full Text] [Related]  

  • 3. Induction of immune tolerance with factor VIII concentrate in patients with hemophilia A and inhibitors.
    Ewing NP
    Prog Clin Biol Res; 1990; 324():59-68. PubMed ID: 2106693
    [No Abstract]   [Full Text] [Related]  

  • 4. Hemophiliac with hemolytic anemia resulting from factor VIII concentrate.
    Soni NS; Patel AR; Vohra RM; Shah PC
    Acta Haematol; 1977; 58(5):294-7. PubMed ID: 413305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-A in factor VIII concentrate: a cause of severe hemolysis in a patient with acquired factor VIII:C antibodies.
    Hach-Wunderle V; Teixidor D; Zumpe P; Kühnl P; Scharrer I
    Infusionstherapie; 1989 Jun; 16(3):100-1. PubMed ID: 2503450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV seroconversion in haemophilic boys receiving heat-treated factor VIII concentrate.
    Williams MD; Skidmore SJ; Hill FG
    Vox Sang; 1990; 58(2):135-6. PubMed ID: 2111060
    [No Abstract]   [Full Text] [Related]  

  • 7. Hemolytic anemia due to anti-B in antihemophiliac factor concentrates.
    Ashenhurst JB; Langehennig PL; Seeler RA; Telfer MC
    J Pediatr; 1976 Feb; 88(2):257-8. PubMed ID: 1249687
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of patients with hemophilia A and inhibitors to factor FVIII with cimetidine.
    Ambriz Fernandez R; Quintana Gonzalez S; Martinez Murillo C; Dominguez Garcia V; Rodriguez Moyado H; Collazo Jaloma J
    Arch Med Res; 1996; 27(1):15-8. PubMed ID: 8867361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group.
    Kessler CM; Ludlam CA
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):22-7. PubMed ID: 8480193
    [No Abstract]   [Full Text] [Related]  

  • 10. Clotting factor concentrated--whither purity?
    Thomas DP
    Thromb Haemost; 1995 Dec; 74(6):1604-6. PubMed ID: 8772244
    [No Abstract]   [Full Text] [Related]  

  • 11. Very-high-purity versus intermediate-purity factor VIII in human immunodeficiency virus-positive hemophiliacs: conclusions of a prospective 3-year study. Monoclate Study Group.
    Seremetis SV
    Semin Hematol; 1993 Oct; 30(4 Suppl 5):10-3. PubMed ID: 7903480
    [No Abstract]   [Full Text] [Related]  

  • 12. [Poly-electrolyte fractionated porcine factor VIII in the treatment of hemophilia A].
    Ferencz T; Skopál J; Csáki C; Laczkó M; Schuler D; Borsi J
    Orv Hetil; 1993 Dec; 134(52):2873-5. PubMed ID: 8272354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purity of concentrates for substitution therapy: acceptable and undesirable contaminants--Madrid 1978.
    Scand J Haematol Suppl; 1980; 35():65-89. PubMed ID: 6770460
    [No Abstract]   [Full Text] [Related]  

  • 14. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
    Klukowska A; Zieleniewska B
    Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
    McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
    Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
    Peerlinck K; Arnout J; Gilles JG; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1993 Feb; 69(2):115-8. PubMed ID: 8456422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hemophilia complicated by inhibitors.
    Scand J Haematol Suppl; 1980; 35():135-64. PubMed ID: 6770458
    [No Abstract]   [Full Text] [Related]  

  • 18. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A.
    Vlot AJ; Mauser-Bunschoten EP; Zarkova AG; Haan E; Kruitwagen CL; Sixma JJ; van den Berg HM
    Thromb Haemost; 2000 Jan; 83(1):65-9. PubMed ID: 10669157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development and characterisation of antibodies to human factor VIII in haemophilic dogs.
    Littlewood JD; Barrowcliffe TW
    Thromb Haemost; 1987 Jun; 57(3):314-21. PubMed ID: 3116702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
    Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
    Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.